[ad_1]
NEW YORK, Sept. 28, 2022 /PRNewswire/ — According to the latest market research report published by P&S Intelligence, with the high risk of blood clots associated with a host of diseases, the anticoagulants market value will reach $42,893.4 million by 2030 from $21,736.2 million in 2021, at a 7.8% CAGR. Moreover, clots themselves can cause coronary artery disease, which is the biggest risk factor for heart attacks and strokes. Since CVDs are already the world’s largest killers, the demand for clot-preventing agents continues to grow .
The number of pharmaceutical companies offering anticoagulants is rather high, owing to the large population of people at a risk of a thrombus or embolus. Hence, pharma companies generally enter into long-term partnerships with medical centers, drug suppliers, and research institutes. Moreover , although the prices of these agents can be high, their sales continue to grow with the rising incidence of clotting disorders.
Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anticoagulant-market-insights/report-sample
In addition, emerging economies offer growth opportunities for pharmaceutical companies, on account of their huge patient population. Coronary artery disease and DVTs are rising in incidence in countries such as China and India as a result of the growing obese population, unhealthy diets, and sedentary lifestyles.
Direct oral anticoagulants (DOACs) are the largest anticoagulants market shareholders, on account of their rising consumption in developing countries. Additionally, after administration, patients do not need extensive cardiovascular monitoring. Further, compared to warfarin, DOACs are better at preventing ischemic strokes and bleeding in people with non-valvular atrial fibrillation. …
Full story available on Benzinga.com
[ad_2]
Source link
